Medicine shortages grow in Iran as US tightens sanctions, blockade

What Happened

Iran is experiencing severe shortages of approximately 800 pharmaceutical products, including 90 classified as essential and life-saving, according to Hadi Ahmadi of the Iranian Pharmacists Association. The crisis is driven by a combination of long-standing United States 'maximum pressure' sanctions and direct military impacts from the ongoing conflict with Israel, which began in February. According to Maryam Farahani, director of sales at Tofigh Daru, Israeli air strikes destroyed the company's research and production lines, which were critical for manufacturing anticancer drugs and other specialized medications. The Israeli military stated in late March that it targeted Tofigh Daru due to allegations that the firm supplied fentanyl to the Ministry of Defence's SPND research body for use in chemical weapons development, a claim the company denies.

Key Actors

Why It Matters

The degradation of Iran's pharmaceutical infrastructure, compounded by a naval blockade and sanctions, has triggered a significant public health crisis. The destruction of specialized production facilities like Tofigh Daru threatens the country's long-term strategy of medical self-sufficiency and exacerbates an existing inflationary spiral that has caused the price of essential medications to rise by as much as 375 percent.

Watch For

Monitor the impact of the ongoing naval blockade in the Strait of Hormuz on the import of critical pharmaceutical ingredients and equipment. Additionally, observe whether the Iranian government implements new subsidies or emergency procurement measures to stabilize the supply of the 90 essential drugs currently in shortage.